膀胱移行细胞癌中p53\nm23和bcl-2的表达及临床意义(2)
 |
| 第1页 |
参见附件(2097KB，3页)。
本组研究中50.0%、48.3%和55.0%的肿瘤有nm23、p53和bcl-2蛋白的异常表达,其中27.7%的肿瘤同时有3种基因的表达异常,表明肿瘤是一个涉及多基因变异的复杂过程。在肿瘤发生发展的不同阶段,多种癌基因、抑癌基因和各种其他因素发挥着不同的作用。多数学者认为肿瘤的发生、浸润和转移至少涉及3个以上癌基因。本实验证实膀胱癌的分级和分期与多基因表达、单多基因表达密切相关。评价膀胱移行细胞癌患者的预后,可以参考上述指标。
参考文献
[1] Smith ND,Rubenstein JN,Eggener SE,et al.The p53 tumor suppressor gene and nuclear protein:basic science review and relevance in the management of bladder cancer.J Urol,2003,169(4):1219-1228.
[2] Fecher G,Perabo G,Schmedt DH,et al.Preclinical evaluation of a radiosensitizing effect of gemacitabine in p53 matant p53 wild type bladder cancer cells.Urology,2003,61(2):468-473.
[3] Malmstrom PU,Ren ZP,Sheriff A,et al.Early metastatic progression of bladder carcinoma:molecular profile of primary tumor and sentinel lymph node.J Urol,2002,168(5):2240-2244.
[4] Steeg PS,Bevilacqua G,Kopper L,et al.Evidence for a novel gene associated with a low tumor potential.J Natl Cancer Inst,1988,80(3):200-204.
[5] Grause FS,Feil G,Bichler KH,et al.Immunohistochemical examinations(Ki67,p53,nm23)and cytophotometry in bladder cancer.Anticancer Res,2000,20(6D):5023-5028.
[6] 崔建国,夏广斌,李光辉,等.Nm23基因表达与膀胱癌生物学行为的关系.中华泌尿外科杂志,1996,17(10):605-608.
[7] Cooke PW,James ND,Canesan R,et al.Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from heoadjuvant chemotherapy.BJU Int,2000,85(7):829-835.
您现在查看是摘要介绍页，详见PDF附件(2097KB，3页)。